Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis - PubMed (original) (raw)
Review
. 2015 Jan 1;37(1):225-241.e8.
doi: 10.1016/j.clinthera.2014.11.008. Epub 2014 Dec 29.
Affiliations
- PMID: 25554560
- DOI: 10.1016/j.clinthera.2014.11.008
Review
Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis
Feng Sun et al. Clin Ther. 2015.
Abstract
Purpose: The goal of this study was to assess the effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on lipid profiles in patients with type 2 diabetes.
Methods: The MEDLINE, Embase, Cochrane Library, and ClinicalTrials.gov databases were searched from inception through October 31, 2013. Randomized controlled trials with available data were selected if they compared GLP-1 RAs with placebo and traditional antidiabetic drugs with a duration ≥8 weeks. The weighted mean difference for changes in lipid profiles was estimated by using the random effects model, and a network meta-analysis was performed to supplement direct comparisons.
Findings: Thirty-five trials with 13 treatments were included in the analysis. GLP-1 RAs decreased HDL-C with a range of -0.06 mmol/L (95% CI, -0.11 to -0.01) to -0.13 mmol/L (95% CI, -0.17 to -0.10) compared with thiazolidinediones, whereas thiazolidinediones were associated with a significant increase in HDL-C compared with placebo (0.09 mmol/L [95% CI, 0.06 to 0.12]). A significant reduction in LDL-C was detected for all GLP-1 RAs versus placebo (range, -0.08 to -0.16 mmol/L), insulin (range, -0.10 to -0.19 mmol/L), and thiazolidinediones (range, -0.16 to -0.24 mmol/L). Exenatide, liraglutide 1.8 mg once daily, and taspoglutide decreased total cholesterol with a range of -0.16 mmol/L (95% CI, -0.26 to -0.06) to -0.27 mmol/L (95% CI, -0.41 to -0.12) versus placebo and thiazolidinediones (range, -0.26 to -0.37 mmol/L). The decreased effect was more evident in exenatide long-acting release and liraglutide 1.8 mg once daily. A significant reduction in triglyceride levels was observed with liraglutide 1.8 mg once daily (-0.30 mmol/L [95% CI, -0.49 to -0.11]) and taspoglutide 20 mg once weekly (-0.17 mmol/L [95% CI, -0.31 to -0.01]) versus placebo.
Implications: GLP-1 RAs were associated with modest reductions in LDL-C, total cholesterol, and triglycerides but no significant improvement in HDL-C. Further evidence is needed to determine if improvements in lipid profiles might translate into reductions in cardiovascular outcomes.
Keywords: GLP-1 receptor agonists; lipid profiles; network meta-analysis; type 2 diabetes.
Copyright © 2015 Elsevier HS Journals, Inc. All rights reserved.
Similar articles
- Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis.
Sun F, Wu S, Guo S, Yu K, Yang Z, Li L, Zhang Y, Ji L, Zhan S. Sun F, et al. Endocrine. 2015 Apr;48(3):794-803. doi: 10.1007/s12020-014-0373-0. Epub 2014 Aug 13. Endocrine. 2015. PMID: 25115635 Review. - Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.
Sun F, Wu S, Guo S, Yu K, Yang Z, Li L, Zhang Y, Quan X, Ji L, Zhan S. Sun F, et al. Diabetes Res Clin Pract. 2015 Oct;110(1):26-37. doi: 10.1016/j.diabres.2015.07.015. Epub 2015 Aug 13. Diabetes Res Clin Pract. 2015. PMID: 26358202 Review. - The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta-analysis.
Dai X, Wang H, Jing Z, Fu P. Dai X, et al. Curr Med Res Opin. 2014 Sep;30(9):1777-86. doi: 10.1185/03007995.2014.921608. Epub 2014 May 28. Curr Med Res Opin. 2014. PMID: 24805140 Review. - [Impact of glucagon-like peptide-1 receptor agonists on nasopharyngitis and upper respiratory tract infection among patients with type 2 diabetes: a network meta-analysis].
Li ZX, Wu SS, Yang ZR, Zhan SY, Sun F. Li ZX, et al. Beijing Da Xue Xue Bao Yi Xue Ban. 2016 Jun 18;48(3):454-9. Beijing Da Xue Xue Bao Yi Xue Ban. 2016. PMID: 27318907 Chinese. - Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, Ni Y, Liu D, Zhu Z. Wang B, et al. Diabetes Obes Metab. 2013 Aug;15(8):737-49. doi: 10.1111/dom.12085. Epub 2013 Mar 20. Diabetes Obes Metab. 2013. PMID: 23433305
Cited by
- Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs.
Le R, Nguyen MT, Allahwala MA, Psaltis JP, Marathe CS, Marathe JA, Psaltis PJ. Le R, et al. J Clin Med. 2024 Aug 9;13(16):4674. doi: 10.3390/jcm13164674. J Clin Med. 2024. PMID: 39200816 Free PMC article. Review. - Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group.
Janez A, Muzurovic E, Bogdanski P, Czupryniak L, Fabryova L, Fras Z, Guja C, Haluzik M, Kempler P, Lalic N, Mullerova D, Stoian AP, Papanas N, Rahelic D, Silva-Nunes J, Tankova T, Yumuk V, Rizzo M. Janez A, et al. Diabetes Ther. 2024 Sep;15(9):1865-1892. doi: 10.1007/s13300-024-01615-5. Epub 2024 Jul 11. Diabetes Ther. 2024. PMID: 38990471 Free PMC article. Review. - Cardiovascular Benefits of GLP-1 Receptor Agonists in Patients Living with Obesity or Overweight: A Meta-analysis of Randomized Controlled Trials.
de Oliveira Almeida G, Nienkötter TF, Balieiro CCA, Pasqualotto E, Cintra JB, Carvalho HCP, Silva ALS, Kabariti JC, Minucci BS, Bertoli ED, Guida CM. de Oliveira Almeida G, et al. Am J Cardiovasc Drugs. 2024 Jul;24(4):509-521. doi: 10.1007/s40256-024-00647-3. Epub 2024 May 11. Am J Cardiovasc Drugs. 2024. PMID: 38734847 - GLP-1RA may have varying effects on cardiac structure in patients with ASCVD depending on BMI.
Xu L, Zhu D. Xu L, et al. Front Endocrinol (Lausanne). 2024 Mar 15;15:1355540. doi: 10.3389/fendo.2024.1355540. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38559688 Free PMC article. - The Role of GLP-1, GIP, MCP-1 and IGFBP-7 Biomarkers in the Development of Metabolic Disorders: A Review and Predictive Analysis in the Context of Diabetes and Obesity.
Jędrysik M, Wyszomirski K, Różańska-Walędziak A, Grosicka-Maciąg E, Walędziak M, Chełstowska B. Jędrysik M, et al. Biomedicines. 2024 Jan 11;12(1):159. doi: 10.3390/biomedicines12010159. Biomedicines. 2024. PMID: 38255264 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical